Plasminogen, alpha 2-antiplasmin, and protein C decline following infusions of recombinant tissue plasminogen activator.
We examined a variety of hemostatic functions in a subset of patients participating in a multicenter trial of rt-PA in the treatment of DVT. There were declines in systemic levels of plasminogen and alpha 2-antiplasmin at 24 hours following therapy. Additionally, levels of protein C antigen and protein C activity were also seen to decrease over the same time course. We propose that therapy with rt-PA has more systemic effects than previously thought and suggest that the effect on protein C may have some role in reocclusion following thrombolysis.
Yang
G
G
Atherosclerosis Program, Northwestern University Medical School, Chicago, Illinois.
Green
D
D
D004357:Drug Synergism; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D010958:Plasminogen / Q000032:analysis*; D011486:Protein C / Q000032:analysis*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use; D013924:Thrombophlebitis / Q000097:blood* / Q000188:drug therapy; D010959:Tissue Plasminogen Activator / Q000494:pharmacology* / Q000627:therapeutic use; D000979:alpha-2-Antiplasmin / Q000032:analysis*
D011486:Protein C; D011994:Recombinant Proteins; D000979:alpha-2-Antiplasmin; D010958:Plasminogen; D006493:Heparin; D010959:Tissue Plasminogen Activator